New cell therapy trial offers hope for Tough-to-Treat lung cancer
NCT ID NCT06097962
Summary
This early-stage study is testing a new combination treatment for advanced non-small cell lung cancer (NSCLC) that has come back or stopped responding to standard therapies. It combines an experimental cell therapy called NK510 with existing PD-1 inhibitor drugs. The study will enroll about 12 people to see if the treatment is safe and if it can help control the cancer, including for patients with fluid buildup around the lungs.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Jinling hospital, affiliated to Medical school Nanjing University
RECRUITINGNanjing, Jiangsu, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.